熱門資訊> 正文

Nuvation Bio，Nurai治疗非小细胞肺癌的申请已被EMA接受

2026-03-27 05:26

EISAI CO(ESALF) 0
EISAI CO UNSPON ADS EACH REP 1 ORD(ESAIY) 0
高宏集團(COWN) 0

The European Medicines Agency has accepted a Marketing Authorisation Application filed by Nuvation Bio (NUVB) and Eisai (ESALF)(ESAIY) for taletrectinib to treat non-small cell lung cancer.
The application was given a standard review time of 210 "active" days. It is supported by data from two pivotal phase 2 studies, TRUST-I and TRUST-II.
Taletrectinib is already marketed as Ibtrozi in the US and Japan.

More on Nuvation Bio, Eisai

Nuvation Bio Inc. (NUVB) Presents at The Citizens Life Sciences Conference 2026 Transcript
Nuvation Bio Inc. (NUVB) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Nuvation Bio Inc. (NUVB) Q4 2025 Earnings Call Transcript
Eli Lilly, Biogen/ Eisai win U.K. review for use of Alzheimer’s drugs in NHS
Nuvation Bio outlines first-line IBTROZI growth strategy with 50-month median DOR amid expanding global partnerships

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。